Skip to content

AI in Drug Discovery & Development

By Sara Mallatt, Director of Healthcare Research and Sean Carmichael

Hype, Reality, and What Comes Next

IndustryLife Sciences & Healthcare

AI has emerged as a powerful potential solution that could revolutionize how drugs are discovered, developed, and brought to patients. AlphaSense recently hosted an expert call with Dr. Paul Agapow, Former Director of Data Science at GSK, to discuss how AI is making inroads in this area.

Drawing from the call with Dr. Agapow, the latest data, and additional expert insights, this report covers how AI is performing against high expectations, what’s working, and what's not. This report also dissects the competitive arena, covering both today’s key players and the mergers, acquisitions, and collaborations that are defining the future.

About the Authors
  • Sara Mallatt

    Sara Mallatt, Director of Healthcare Research

    Sara has more than 18 years of experience generating sell-side research content across a variety of industries. Prior to joining AlphaSense, Sara held leadership positions at OTR Global, a leading channel research firm, most recently as Director of Healthcare Research. Sara holds a bachelor’s degree in journalism and a master’s in industrial engineering. She works from her home in Missoula, Montana.
  • Sean Carmichael

    Sean Carmichael

    Sean is a Business & Finance Editor at AlphaSense, specializing in sector-specific content production. Previously, he spent nearly a decade in various roles across financial services, where he was responsible for equity research and content generation geared toward institutional investors.

Explore more

All articles

Luxury at an Inflection Point: What the Numbers Aren’t Telling Investors

Luxury has enjoyed close to four decades of near-continuous growth, and the industry has come to view that run as a baseline rather than an exception.
ReportConsumer/CPGFinancial Services
Dark blue graphic with the title "Luxury at an Inflection Point: What the Numbers Aren't Telling Investors." Features blue line drawings of a watch, handbag, and high heels, with text mentioning interviews with LVMH and Prada executives.

Key Debates Transforming Healthcare and Life Sciences in 2026

2026 is a year of transition for healthcare and life sciences as the industry moves toward more convenient, patient-centric care.
ReportLife Sciences & HealthcareFinancial Services
A graphic titled "Key Debates Transforming Healthcare and Life Sciences in 2026", featuring stylized illustrations of a medicine bottle, a pill, a microscope, and a DNA helix on a blue background.

Key Debates Transforming Technology, Media, and Telecom in 2026

In this report, we harness broker research, Tegus Expert Insights, and company commentary in AlphaSense to explore how the debates below are shaping the technology, media, and telecom landscape in 2026.
Report
Blue line art illustration with the title "Key Debates Transforming Technology, Media, and Telecom in 2026," featuring a CPU, server rack, and an airplane.

Transform intelligence
into advantage

Develop bold strategies, seize opportunities,
and lead with clarity and confidence.